PMID- 25445469
OWN - NLM
STAT- MEDLINE
DCOM- 20151120
LR  - 20150227
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 15
IP  - 3
DP  - 2015 Mar
TI  - Characteristics of patients with development of large granular lymphocyte 
      expansion among dasatinib-treated patients with relapsed Philadelphia 
      chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell 
      transplantation.
PG  - e47-54
LID - S2152-2650(14)00416-9 [pii]
LID - 10.1016/j.clml.2014.09.006 [doi]
AB  - INTRODUCTION: Widespread use of tyrosine kinase inhibitors (TKIs) in combination 
      with chemotherapy and allogeneic hematopoietic stem cell transplantation 
      (allo-SCT) has totally changed the existing treatment strategies for Philadelphia 
      chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL). However, the 
      prognosis after relapse after allo-SCT is still dismal. PATIENTS AND METHODS: We 
      analyzed the clinical outcome of therapy using dasatinib, a second-generation 
      TKI, in 9 patients with relapsed Ph(+)ALL after allo-SCT. Dasatinib was initiated 
      at a median time of 168 days after allo-SCT at dosages ranging from 20 mg to 100 
      mg daily. RESULTS: Six of 9 patients manifested a marked increase in large 
      granular lymphocytes (LGLs), but all 6 patients discontinued dasatinib because of 
      adverse events (AEs) such as pleural effusion. Four of 6 patients resumed 
      dasatinib, and 3 of them have been alive with molecular complete remission and a 
      persistent increase of LGLs. CONCLUSION: Our results demonstrated that dasatinib 
      therapy can induce LGL expansion accompanied by AEs, but this phenomenon can be 
      associated with long-term survival benefit in a proportion of relapsed Ph(+)ALL 
      patients after allo-SCT.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Ito, Yoshikiyo
AU  - Ito Y
AD  - Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan; 
      Department of Hematology, Harasanshin Hospital, Fukuoka, Japan.
FAU - Miyamoto, Toshihiro
AU  - Miyamoto T
AD  - Department of Medicine and Biosystemic Science, Graduate School of Medical 
      Science, Kyushu University, Fukuoka, Japan. Electronic address: 
      toshmiya@intmed1.med.kyushu-u.ac.jp.
FAU - Kamimura, Tomohiko
AU  - Kamimura T
AD  - Department of Hematology, Harasanshin Hospital, Fukuoka, Japan.
FAU - Aoki, Kenichi
AU  - Aoki K
AD  - Department of Hematology, Japan Community Health care Organization Kyushu 
      Hospital, Kitakyushu, Japan.
FAU - Henzan, Hideho
AU  - Henzan H
AD  - Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
FAU - Aoki, Takatoshi
AU  - Aoki T
AD  - Department of Hematology, Harasanshin Hospital, Fukuoka, Japan.
FAU - Shiratsuchi, Motoaki
AU  - Shiratsuchi M
AD  - Department of Medicine and Bioregulatory Science, Graduate School of Medical 
      Science, Kyushu University, Fukuoka, Japan.
FAU - Kato, Koji
AU  - Kato K
AD  - Department of Medicine and Biosystemic Science, Graduate School of Medical 
      Science, Kyushu University, Fukuoka, Japan.
FAU - Nagafuji, Koji
AU  - Nagafuji K
AD  - Division of Hematology and Oncology, Department of Medicine, Kurume University 
      School of Medicine, Kurume, Japan.
FAU - Ogawa, Ryosuke
AU  - Ogawa R
AD  - Department of Hematology, Japan Community Health care Organization Kyushu 
      Hospital, Kitakyushu, Japan.
FAU - Eto, Tetsuya
AU  - Eto T
AD  - Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
FAU - Iwasaki, Hiromi
AU  - Iwasaki H
AD  - Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, 
      Japan.
FAU - Akashi, Koichi
AU  - Akashi K
AD  - Department of Medicine and Biosystemic Science, Graduate School of Medical 
      Science, Kyushu University, Fukuoka, Japan.
LA  - eng
PT  - Journal Article
DEP - 20140928
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - RBZ1571X5H (Dasatinib)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Biopsy
MH  - Bone Marrow/pathology
MH  - Combined Modality Therapy
MH  - Consolidation Chemotherapy
MH  - Dasatinib/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Graft vs Host Disease/etiology
MH  - Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Induction Chemotherapy
MH  - Lymphocytes/*pathology
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Neoplasm, Residual
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics/*pathology/*therapy
MH  - Protein Kinase Inhibitors/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Recurrence
MH  - Retrospective Studies
MH  - Transplantation, Homologous
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adverse events
OT  - Allogeneic stem cell transplantation
OT  - Dasatinib
OT  - Large granular lymphocyte
OT  - Philadelphia-positive ALL
EDAT- 2014/12/03 06:00
MHDA- 2015/12/15 06:00
CRDT- 2014/12/03 06:00
PHST- 2014/07/25 00:00 [received]
PHST- 2014/09/06 00:00 [revised]
PHST- 2014/09/17 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S2152-2650(14)00416-9 [pii]
AID - 10.1016/j.clml.2014.09.006 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):e47-54. doi: 
      10.1016/j.clml.2014.09.006. Epub 2014 Sep 28.